PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Lormetazepam→

Lormetazepam PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
848-75-9
Molecular formula
C16H12Cl2N2O2
Molecular weight
335.2 g/mol
Drug class
Benzodiazepine hypnoticpositive allosteric modulator of GABAA receptors
Mechanism of action
Binds to the benzodiazepine regulatory site on GABAA receptors and enhances the effect of endogenous GABA, increasing chloride-channel opening and neuronal inhibition.
Indications / reported uses
  • Short-term treatment of severe insomnia when it is disabling or causing significant distress, in accordance with the product label.

Sources: https://www.medicines.org.uk/emc/product/5269/smpc · https://pubchem.ncbi.nlm.nih.gov/compound/13314 · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Lormetazepam PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Lormetazepam Permitted Daily Exposure (PDE) report (the Lormetazepam PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Lormetazepam Occupational Exposure Limit (OEL) report (the Lormetazepam OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.